You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
貝康醫療(2170.HK):貝康子公司BMX與美國Gattaca Genomics 獲倫理審查委員會批准展開全時差技術與基因檢測研究合作 預計佈局100個醫院網點
格隆匯 10-10 12:20
昨日,Gattaca Genomics通過美通社宣佈與全球領先的輔助生殖技術(ART)公司Genea Biomedx建立全新合作伙伴關係。此次合作支持一項獲得聯邦倫理審查委員會批准的重要研究,該研究將Genea Biomedx的尖端全時差延時成像技術與Gattaca Genomics的基因檢測技術相結合。兩家公司將共同應用各自的先進技術,顯著改善體外受精中的胚胎選擇,並提高全球患者的臨牀效果。作為合作的一部分,Genea Biomedx將獨家銷售其先進的Geri全時差培養箱,並選擇參與該研究的試管嬰兒診所。Geri能夠對胚胎髮育進行連續、實時監測,確保最佳培養條件並收集寶貴數據。此項名為“利用全時差延時成像結合下一代測序的植入前非整倍性基因檢測進行胚胎評估”的研究,將把Geri的高分辨率成像與Gattaca Genomics的前沿基因檢測解決方案相結合。通過整合雙方的優勢,合作目標是開發一個全面的數據集,以重新定義健康胚胎的選擇方式,從而提升試管嬰兒的成功率和臨牀結果。此次合作將Genea Biomedx的技術創新與Gattaca Genomics的基因專業結合,為不斷增長的試管嬰兒市場開闢新的機遇。合作將為全球約100家試管嬰兒診所提供能夠提高患者成功率和臨牀效率的綜合解決方案,進一步推動對Geri全時差培養箱和先進基因檢測的需求。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account